Profil
Didier Véron is a Member-Supervisory Board at Leem.
He was a Director-Corporate Communications at Tercica, Inc. from 2012 to 2014.
He was also a SVP-Public Affairs & Corporate Communications at Ipsen SA from 2013 to 2018.
Mr. Véron has an undergraduate degree from Sciences Po and a graduate degree from Université de Paris XI Paris Sud.
Aktive Positionen von Didier Véron
| Unternehmen | Position | Beginn |
|---|---|---|
| Leem | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Didier Véron
| Unternehmen | Position | Ende |
|---|---|---|
| IPSEN | Public Communications Contact | 01.12.2018 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Public Communications Contact | 03.02.2014 |
Ausbildung von Didier Véron
| Sciences Po | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IPSEN | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Leem | |
| Université de Paris XI Paris Sud | Consumer Services |
